Dalbavancin + Vancomycin + Oxacillin + Flucloxacillin + Cefadroxil + Clindamycin
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Methicillin-Resistant Staphylococcus Aureus
Conditions
Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections, Staphylococcal Skin Infections
Trial Timeline
Mar 30, 2017 → Jan 1, 2024
NCT ID
NCT02814916About Dalbavancin + Vancomycin + Oxacillin + Flucloxacillin + Cefadroxil + Clindamycin
Dalbavancin + Vancomycin + Oxacillin + Flucloxacillin + Cefadroxil + Clindamycin is a phase 3 stage product being developed by AbbVie for Methicillin-Resistant Staphylococcus Aureus. The current trial status is completed. This product is registered under clinical trial identifier NCT02814916. Target conditions include Methicillin-Resistant Staphylococcus Aureus, Bacterial Infections, Staphylococcal Skin Infections.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02814916 | Phase 3 | Completed |
Competing Products
2 competing products in Methicillin-Resistant Staphylococcus Aureus
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Imipenem/cilastatin | Pfizer | Approved | 84 |
| Linezolid + Vancomycin | Pfizer | Pre-clinical | 22 |